Trending...
- Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match
- LocalsVoted Launches: Local Rankings From Phone-Verified Votes, Not Paid Placement
- Spokane Police is Seeking Assistance Locating a Missing Adult Male
STUART, Fla., April 19, 2024 ~ Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is making strides in the development of therapies for various eye disorders. The company's President and CEO, Eric Schlumpf, will be presenting their latest research results at two upcoming meetings in early May.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
- Charlie Shaw and Patrick Carragher win SEO Agency of the Year 2026
- Canadian Woman Plants 1,667 Love Stories in a Field of Peonies That Could Bloom for 100 Years
- New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
- Proform Builds Releases Short Documentary on Founder Joey Fentress and the Story Behind the Company
- Tacoma City Council Passes Ordinance to Modernize Property Maintenance Standards, Address Repeat and Chronic Violations, and Strengthen Neighborhood Livability
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
0 Comments
Latest on Washingtoner
- Call 311 for Non-Emergency Help in City of Spokane Limits
- Paraguay Expedition Offers a Different View of Human Resilience
- Longevity Academy Features Gail Humble, MD of KLOTHO SKIN in the Longevity Leaders Project
- Datavalet Named One of Quebec's Best Workplaces™ for 2026
- Phinge Corporation Engages Sheridan Ross PC for Certain Intellectual Property Matters
- Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers
- Slotozilla Hosts Exclusive Halloween Casino Bonuses for 2026
- Remcon Equipment Marks 35 Years as a Conveyor Company, With 1,500+ Systems Built
- "BROOKLYN, BROOKLYN, BROOKLYN" children's book and official YouTube channel launch on October 27th
- Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
- Nextlink Internet Deploys netElastic to Modernize Its Hybrid Broadband Network
- Dynamic Relaunch as AI Predictive Cybersecurity Company Optimized to Prevent Threats Proactively: Cycurion, Inc. (N A S D A Q: CYCU)
- EMBER™ Unveils the Workplace Identity Score™ (WIS™), the First Standard for Measuring Workplace Impact on Workforce Performance & Business Growth
- With Oil Prices Surging…Sky Quarry's Nevada Refinery Is Back in Action — CEO Highlights a Powerful New Growth Chapter for (N A S D A Q: SKYQ)
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Win Gold in Raleigh's Best Awards for Second Consecutive Year
- We are Talker Study: 64% of AI Users Have Bought From a Brand AI Introduced, as The Invisible Shortlist Reshapes Brand Discovery
- One in three Americans may have lost track of retirement savings from a previous job
- Political Concerns Drive US Investors to Golden Visas
- Tacoma: T-Town Takes Over the Dome Oct. 30
- New Book Savvy Not Sabotaged Helps Those Hurt by Betrayal Set Boundaries Without Shutting Others Out